Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
4(80.0%)
Phase 3
1(20.0%)
5Total
Phase 2(4)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03592862Phase 2Withdrawn

A Study to Assess Safety, Tolerability, and Efficacy of HTL0018318 in Patients With Dementia With Lewy Bodies

Role: collaborator

NCT00635063Phase 3Terminated

A Multicentre Study to Evaluate the Safety and Efficacy of AD 923 in Comparison to MSIR for the Treatment of CBP in Subjects

Role: lead

NCT00377039Phase 2Completed

A Multicentre Trial to Determine the Efficacy and Safety of AD-337 in the Treatment of Fibromyalgia

Role: lead

NCT00141934Phase 2Completed

A Multicentre Trial to Determine the Efficacy of AD 452 in RA Subjects.

Role: lead

NCT00242333Phase 2Completed

A Study to Assess the Safety and Efficacy of Different AD 237 Doses in Adults With COPD

Role: lead

All 5 trials loaded